Department of Organic Chemistry C. Nenitescu, Faculty of Applied Chemistry and Science of Materials, Polytechnic University of Bucharest, Bucharest, Romania.
Pharmacol Rep. 2013;65(3):743-50. doi: 10.1016/s1734-1140(13)71054-5.
Paraoxonase-1 (PON1) is one of the HDL-associated proteins which contributes to the antioxidant properties of these lipoproteins. The aim of this pilot study was to evaluate the effect of the nutritional supplement ALAnerv® on serum PON1 activity in post-acute stroke patients undergoing rehabilitation.
We enrolled 28 post-acute stroke patients and randomly divided them into (-) ALA or (+) ALA study groups. All the patients underwent the same rehabilitation program and received comparable standard medications. Moreover, (+) ALA patients received ALAnerv® for two weeks (2 pills/day). The serum PON1 activity was assessed on blood samples taken at the admission and at the discharge moments, respectively. We used paraoxon (paraoxonase activity, PONA), phenyl acetate (arylesterase activity, ARYLA) and dihydrocoumarin (lactonase activity, LACTA) as substrates, the latter activity being regarded as physiologically relevant. A control group of 14 apparently healthy subjects was also created.
In the (+) ALA group, LACTA significantly increased during the study period (17.6 ± 3.2 vs. 27.6 ± 3.5, p = 0.002). Moreover, the percentage of LACTA variation between (-) ALA and (+) ALA groups during the study was also statistically different (-11.7 ± 6.9% vs. +95.1 ± 29.7%, p < 0.0001).
These preliminary results suggest that ALA nerv® could contribute to the improvement of the physiologically relevant LACTA of PON1 in post-acute stroke patients, enabling this enzyme to contribute to the redox correction. Also, this study raises the question about the effect of a longer treatment period over the other enzymatic activities of serum PON1.
对氧磷酶 1（PON1）是与高密度脂蛋白（HDL）相关的蛋白之一，其有助于这些脂蛋白的抗氧化特性。本初步研究的目的是评估营养补充剂 ALAnerv®对接受康复治疗的急性后期脑卒中患者血清 PON1 活性的影响。
我们纳入了 28 名急性后期脑卒中患者，并将其随机分为（-）ALA 或（+）ALA 研究组。所有患者均接受相同的康复计划和类似的标准药物治疗。此外，（+）ALA 患者接受 ALAnerv®治疗两周（每天 2 片）。分别在入院时和出院时采集血清样本以评估血清 PON1 活性。我们使用对氧磷（对氧磷酶活性，PONA）、苯乙酸酯（芳酯酶活性，ARYLA）和二氢香豆素（内酯酶活性，LACTA）作为底物，后者的活性被认为与生理相关。还创建了一个由 14 名健康对照者组成的对照组。
在（+）ALA 组，LACTA 在研究期间显著增加（17.6 ± 3.2 与 27.6 ± 3.5，p = 0.002）。此外，研究期间（-）ALA 和（+）ALA 组之间的 LACTA 变化百分比也存在统计学差异（-11.7 ± 6.9%与 +95.1 ± 29.7%，p < 0.0001）。
这些初步结果表明，ALA nerv®可能有助于改善急性后期脑卒中患者血清 PON1 中与生理相关的 LACTA，使该酶能够有助于氧化还原纠正。此外，本研究提出了关于更长治疗期对血清 PON1 其他酶活性影响的问题。
